SERVIER
“WE ARE COMMITTED TO THERAPEUTIC PROGRESS TO SERVE PATIENT NEEDS”
“Where there is love of humankind, there is also love of the art of medicine”
Hippocrates
ABOUT SERVIER HELLAS
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities, from research to support beyond the pill.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.
Oriented towards the future, through our actions, we contribute to transmit to future generations a world that can ensure access to quality health care for all.
Our values are the source of inspiration and guidance for achieving our vision: Care, Dare to Innovate, Commit to Succeed and Grow by Sharing.
CONTACT
General Manager: Estève Speranza
Number of employees (15/03/2022): 84 people
Address: 7 Fragkoklissias str, 151 25 Maroussi, Athens
- Telephone:+30 (210) 9391 000
- Fax:+30 (210) 9391 001
- Website: https://servier.com/en/